IP Library Granted Patent US 12673119
Granted Patent B2
US 12673119 · App. 18/096,718 · Granted Jul 7, 2026

Non-human mammal model of human degenerative disorder, uses thereof, and method of treating human degenerative disorder

Inventor: Steven A. Goldman (Webster, NY)
Assignee: University of Rochester
A61K49/0008A01K67/0271A61K35/30A61K35/545A61K45/06C12N5/06C12N5/0622G01N33/50G01N33/5085A01K2207/12A01K2207/15A01K2227/105A01K2267/0318G01N2800/28G01N2800/2814G01N2800/2821G01N2800/2835
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12673119
App. No.
18/096,718
Granted
Jul 7, 2026
Kind
B2
Abstract

The present application relates to a non-human mammal model of a human neurodegenerative disorder, methods of producing the non-human mammal model, and methods of using the non-human mammal model to identify agents suitable for treating a neurodegenerative disorder. The present application also relates to methods of treating neurodegenerative disorders and restoring normal brain interstitial potassium levels.

Claims (8)

1 . A method of restoring normal brain interstitial K + levels in a subject with dysregulated glial K + channel function, said method comprising: selecting a subject having dysregulated K + channel function; and administering to the selected subject a preparation of glial progenitor cells that are both CD140a+ and CD44+ at a dosage effective to restore normal brain interstitial glial K + levels in the selected subject.

2 . The method of claim 1 , wherein the dysregulated glial K+ channel function is characterized by defective K+ conductance, defective K+ uptake, and/or defective K+ channel expression.

3 . The method of claim 1 , wherein the preparation of glial progenitor cells are astrocyte-biased glial progenitor cells.

4 . The method of claim 1 , wherein the glial progenitor cells of the preparation are further A2B5+.

5 . The method of claim 1 , wherein said preparation of glial progenitor cells is administered to the striatum of the subject.

6 . The method of claim 1 , wherein the subject is a human.

7 . The method of claim 1 , wherein the glial progenitor cells are human glial progenitor cells.

8 . The method of claim 1 , wherein the glial progenitor cells are derived from fetal tissue, embryonic stem cells, or induced pluripotent stem cells.